PT  - JOURNAL ARTICLE
AU  - Ye, Xufeng
AU  - Wang, Xinpei
AU  - Jia, Jinzhu
TI  - Proteome-wide Mendelian Randomization Analysis Identified Potential Drug Targets for Myocardial Infarction
AID  - 10.1101/2023.12.05.23299535
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.12.05.23299535
4099  - http://medrxiv.org/content/early/2023/12/06/2023.12.05.23299535.short
4100  - http://medrxiv.org/content/early/2023/12/06/2023.12.05.23299535.full
AB  - Background Myocardial infarction (MI) is a leading cause of global mortality. Finding effective drugs to treat MI is an urgent concern for clinicians. Proteome-wide Mendelian randomization (MR) analysis provides a new way to investigate invaluable therapeutic drug targets more efficiently.Methods Using a proteome-wide MR approach, we assessed the genetic predictive causality between thousands of plasma proteins and MI risk. First, by adopting several principles to judge genetic variants associated with plasma proteins and MI risk, we selected a series of suitable variants utilized as instrumental variables (IVs) for the latter Mendelian Randomization (MR) analysis. Second, we performed a proteome-wide MR analysis to select candidate proteins. Third, sensitivity tests including heterogeneity test, reverse causality test, and colocalization analyses were conducted to ensure the robustness of our selected protein. Last, we assessed the drugability of the identified potential drug targets for MI using databases including DrugBank, PharmGKB, and TTD.Results Of the identified IVs, 3,156 associated with 1,487 plasma proteins were validated. 15 proteins exhibited significant genetically predicted causal associations(P − value < 3.362∗10−5) with MI risk, including Plasmin, MSP, Apo B, TAGLN2, LRP4, C1s, Angiostatin, Apo C-III, PCSK9, ANGL4, FN1.4,Apo B, IL-6 sRa, SWAP70, FN, FN1.3. Sensitivity analyses pinpointed Plasmin and Angiostatin for heterogeneity and proteins MSP, Apo B, and Angiostatin for reverse causality effects. Colocalization analysis found several proteins sharing genetic variants with MI, notably Apo B, TAGLN2, LRP4, C1s, Apo C-III, PCSK9 and ANGL4. When the threshold was lowered to 0.7, additional variants SWAP70 could be contained. 7 potential drug targets for MI were identified: SWP70, TAGLN2, LRP4, C1s, Apo C-III, PCSK9, and ANGL4. Drugability assessment categorized these proteins into varying therapeutic potential categories, from successfully drugged targets to those only reported in the literature.Conclusion Our comprehensive study elucidated 7 promising drug targets offering profound insights into its molecular dynamics and presenting potential pathways for therapeutic interventions against MI.1) What Is New?★ The analysis of thousands of proteins has identified 7 proteins that have a potential causal role in myocardial infarction risk.★ Four of these ten proteins have drugs approved or in development that target them, and three 5 have not been previously reported to be associated with atrial fibrillation risk.2) What Are the Clinical Implications?★ The results of the present study demonstrate new potential drug/therapeutic targets for myocardial infarction.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialDeclaration:It's not a clinical trial.Funding StatementSources of Funding This work was supported by Peking University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Full summary statistics relating to the GWAS analysis in the UK Biobank and the analysis with CARDIoGRAMplusC4D will be deposited with The NHGRI-EBI Catalog of published genome-wide association studies (https://www.ebi.ac.uk/gwas/docs/about).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe database for genetic variations associated with plasma proteins has been sourced from deCODE genetics/Amgen, Inc., Reykjavik, Iceland. The database for genetic variations associated with myocardial infarction (MI) has been obtained from two major repositories: the UK BioBank and the CARDIoGRAM+C4D Consortium. Both of these databases are publicly accessible, in accordance with data sharing policies.https://www.decode.com/summarydatahttps://www.nature.com/articles/s41588-021-00978-w#MOESM4https://academic.oup.com/eurheartj/article/42/9/919/6126843#supplementary-datahttp://db.idrblab.net/ttd/https://www.pharmgkb.org/https://go.drugbank.com/https://www.ebi.ac.uk/gwas/studies/GCST011365MImyocardial infarctionFDAFood and Drug AdministrationGWASgenome-wide association studyIVinstrumental variableIVWinverse variance weighted methodLDlinkage disequilibriumMAFminor allele frequencyMHCmajor histocompatibility complexMRmendelian randomizationpQTLquantitative trait locusSNPsingle nucleotide polymorphismTTDtherapeutic target database